Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Benign Prostate Hyperplasia Clear all
Terminated Phase 2 Interventional

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Microspheres
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
28
States / cities
Huntsville, Alabama • Anchorage, Alaska • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Early Phase 1 Interventional

Ultrasound-Guided Photoselective Vaporization of the Prostate

NCT02346500
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Transrectal Ultrasound
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells

NCT02425800
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Carcinoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

NCT07538622
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Zenflow Spring System
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • La Mesa, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Phase 4 Interventional

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

NCT00690950
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Dutasteride
Drug
Lead sponsor
Urologic Consultants of Southeastern PA
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization

NCT00465101
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight HPS
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
45 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Middlebury, Connecticut • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated No phase listed Observational

IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation

NCT06157164
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

NCT00793819
View directory record Official record
Conditions
Nocturia, Prostatic Hyperplasia
Interventions
silodosin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
27
States / cities
Huntsville, Alabama • Laguna Hills, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

NCT02506465
View directory record Official record
Conditions
Benign Prostate Hyperplasia
Interventions
iTIND, Sham Arm
Device · Procedure
Lead sponsor
Medi-Tate Ltd.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Pompano Beach, Florida • Baltimore, Maryland • Brooklyn, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional Results available

Optilume™ BPH Catheter System in Men With Symptomatic BPH

NCT04131907
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Optilume BPH Catheter System, Optilume Sham Device
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Little Rock, Arkansas • Golden, Colorado • Daytona Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Post-Market Study to Assess iTind Safety in Comparison to UroLift

NCT04757116
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
iTind, UroLift
Device · Procedure
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
50 Years and older · Male only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

NCT02961114
View directory record Official record
Conditions
BPH, Nocturia, BPH With Urinary Obstruction, Prostatism, Prostate Inflammation
Interventions
Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
Procedure · Device · Biological
Lead sponsor
Robert W. Alexander, MD, FICS
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Phase 4 Interventional

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

NCT00826527
View directory record Official record
Conditions
Urinary Frequency, Urinary Urgency, Nocturia
Interventions
Solifenacin PO
Drug
Lead sponsor
Seattle Urology Research Center
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT00709488
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Talaporfin sodium, Placement of device in prostate urethra, Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Drug · Procedure · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Anchorage, Alaska • Los Angeles, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

NCT00645034
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
placebo, sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
35 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Laguna Woods, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

NCT05400980
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urocross implant, Sham-control
Device · Diagnostic Test
Lead sponsor
Prodeon Medical, Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Maywood, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia

NCT04398966
View directory record Official record
Conditions
BPH, Enlarged Prostate (BPH), Prostatic Hyperplasia
Interventions
Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Deprescribing Tamsulosin in Older Men

NCT05415748
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 80 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated No phase listed Observational

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 17, 2026, 4:08 AM EDT